Psoriasis: the epidermal component

Clinics in Dermatology

Volumn 25, Issue 6, 2007, Pages 589-595

  Tschachler, Erwin ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CHRONICITY; DISEASE MODEL; DISEASE PREDISPOSITION; EPIDERMIS; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC LINKAGE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RELAPSE; SKIN INFLAMMATION;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; EPIDERMIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KERATINOCYTES; LYMPHOCYTE ACTIVATION; PSORIASIS;

EID: 36048935579     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.09.021     Document Type: Article

References (72)

1. Sterry W., Barker J., Boehncke W.H., et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 151 Suppl 69 (2004) 3-17
2. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
3. Ghadially R., Reed J.T., and Elias P.M. Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol 107 (1996) 558-564
4. Stingl G., Maurer M., Hauser C., and Wolff K. The skin: an immunological barrier. In: Freedber I.M., Eisen A.Z., Wolff K., Austen F., Goldsmith L.A., and Katz S.I. (Eds). Dermatology in general medicine (2003), McGraw-Hill, New York 253-273
5. Nickoloff B.J., and Stevens S.R. What have we learned in dermatology from the biologic therapies?. J Am Acad Dermatol 54 3 Suppl 2 (2006) S143-S151
6. Lin W.J., Norris D.A., Achziger M., et al. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 117 (2001) 1546-1553
7. Griffiths C.E., and Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 370 (2007) 263-271
8. Bovenschen H.J., Seyger M.M., and Van de Kerkhof P.C. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 153 (2005) 72-78
9. Hohl D. Expression patterns of loricrin in dermatological disorders. Am J Dermatopathol 15 (1993) 20-27
10. Bernard B.A., Asselineau D., Schaffar-Deshayes L., and Darmon M.Y. Abnormal sequence of expression of differentiation markers in psoriatic epidermis: inversion of two steps in the differentiation program?. J Invest Dermatol 90 (1988) 801-805
11. Lippens S., Kockx M., Denecker G., et al. Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. Am J Pathol 165 (2004) 833-841
12. Fischer H., Eckhart L., Mildner M., et al. DNase1L2 degrades nuclear DNA during corneocyte formation. J Invest Dermatol 127 (2007) 24-30
13. Bernerd F., Magnaldo T., and Darmon M. Delayed onset of epidermal differentiation in psoriasis. J Invest Dermatol 98 (1992) 902-910
14. Koizumi H., Kartasova T., Tanaka H., Ohkawara A., and Kuroki T. Differentiation-associated localization of small proline-rich protein in normal and diseased human skin. Br J Dermatol 134 (1996) 686-692
15. Mommers J.M., van Rossum M.M., van Erp P.E., and van De Kerkhof P.C. Changes in keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of spreading psoriasis. Dermatology 201 (2000) 15-20
16. Harder J., and Schröder J.M. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 77 (2005) 476-486
17. Hertle M.D., Kubler M.D., Leigh I.M., and Watt F.M. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89 (1992) 1892-1901
18. Watson R.E., Poddar R., Walker J.M., et al. Altered claudin expression is a feature of chronic plaque psoriasis. J Pathol 212 (2007) 450-458
19. Peltonen S., Riehokainen J., Pummi K., and Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol 156 (2007) 466-472
20. Candi E., Oddi S., Paradisi A., et al. Expression of transglutaminase 5 in normal and pathologic human epidermis. J Invest Dermatol 119 (2002) 670-677
21. Wakugawa M., Nakamura K., Akatsuka M., Nakagawa H., and Tamaki K. Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1beta, TNF-alpha, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus. Dermatology 202 (2001) 239-245
22. Wei L., Debets R., Hegmans J.J., Benner R., and Prens E.P. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 187 (1999) 358-364
23. Sandilands A., Smith F.J., Irvine A.D., and McLean W.H. Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 127 (2007) 1282-1284
24. Powles A.V., Baker B.S., Rutman A.J., McFadden J.P., Valdimarsson H., and Fry L. Epidermal rupture is the initiating factor for the Koebner response in psoriasis. Acta Derm Venereol 70 (1990) 35-38
25. Gerritsen M.J., van Pelt J.P., and van de Kerkhof P.C. Response of the clinically uninvolved skin of psoriatic patients to tape stripping during acitretin treatment. Acta Derm Venereol 76 (1996) 6-9
26. Hwang S.M., Ahn S.K., Menon G.K., Choi E.H., and Lee S.H. Basis of occlusive therapy in psoriasis: correcting defects in permeability barrier and calcium gradient. Int J Dermatol 40 (2001) 223-231
27. Menter A., and Griffiths C.E. Current and future management of psoriasis. Lancet 370 (2007) 272-284
28. Dusso A.S., Brown A.J., and Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 289 (2005) F8-F28
29. Schambach F., Schupp M., Lazar M.A., and Reiner S.L. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 37 (2007) 2396-2399
30. Elder J.T., Fisher G.J., Lindquist P.B., et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243 (1989) 811-814
31. Cook P.W., Pittelkow M.R., Keeble W.W., Graves-Deal R., Coffey Jr. R.J., and Shipley G.D. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 52 (1992) 3224-3227
32. Cook P.W., Pittelkow M.R., and Piepkorn M. Overexpression of amphiregulin in the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype. J Invest Dermatol 113 (1999) 860
33. Vassar R., and Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5 (1991) 714-727
34. Detmar M., Brown L.F., Claffey K.P., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
35. Detmar M., Brown L.F., Schön M.P., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111 (1998) 1-6
36. Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., and Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
37. Iizuka H., Takahashi H., and Ishida-Yamamoto A. Pathophysiology of generalized pustular psoriasis. Arch Dermatol Res 295 (2003) S55-S59
38. Sticherling M., Bornscheuer E., Schroder J.M., and Christophers E. Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol 96 (1991) 26-30
39. Kojima T., Cromie M.A., Fisher G.J., Voorhees J.J., and Elder J.T. GRO-alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes. J Invest Dermatol 101 (1993) 767-772
40. Homey B., Dieu-Nosjean M.C., Wiesenborn A., et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164 (2000) 6621-6632
41. Broome A.M., Ryan D., and Eckert R.L. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 51 (2003) 675-685
42. Gottlieb A.B., Chamian F., Masud S., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729
43. Kock A., Schwarz T., Kirnbauer R., et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 172 (1990) 1609-1614
44. Gudjonsson J.E., Johnston A., Dyson M., Valdimarsson H., and Elder J.T. Mouse models of psoriasis. J Invest Dermatol 127 (2007) 1292-1308
45. Wrone-Smith T., and Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J Clin Invest 98 (1996) 1878-1887
46. Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., and Nestle F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199 (2004) 731-736
47. Sugai J., Iizuka M., Kawakubo Y., et al. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 17 (1998) 85-92
48. Barker C.L., McHale M.T., Gillies A.K., et al. The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 123 (2004) 892-901
49. Li A.G., Wang D., Feng X.H., and Wang X.J. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23 (2004) 1770-1781
50. Li Q., Lu Q., Hwang J.Y., et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13 (1999) 1322-1328
51. Pasparakis M., Courtois G., Hafner M., et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417 (2002) 861-866
52. Angel P., Szabowski A., and Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20 (2001) 2413-2423
53. Mehic D., Bakiri L., Ghannadan M., Wagner E.F., and Tschachler E. Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol 124 (2005) 212-220
54. Eckert R.L., and Welter J.F. Transcription factor regulation of epidermal keratinocyte gene expression. Mol Biol Rep 23 (1996) 59-70
55. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
56. Johansen C., Kragballe K., Rasmussen M., Dam T.N., and Iversen L. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br J Dermatol 151 (2004) 600-607
57. Haider A.S., Duculan J., Whynot J.A., and Krueger J.G. Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J Invest Dermatol 126 (2006) 912-914
58. Zenz R, Eferl R, Scheinecker C, et al. The role of AP-1 in disease pathways with specific reference to psoriasis and psoriatic arthritis. Arthritis Res Ther (in press).
59. Sano S., Chan K.S., Carbajal S., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11 (2005) 43-49
60. Liu Y., Krueger J.G., and Bowcock A.M. Psoriasis: genetic associations and immune system changes. Genes Immun 8 (2007) 1-12
61. Capon F., Trembath R.C., and Barker J.N. An update on the genetics of psoriasis. Dermatol Clin 22 (2004) 339-347
62. Asumalahti K., Ameen M., Suomela S., et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120 (2003) 627-632
63. Allen M.H., Ameen H., Veal C., et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 124 (2005) 103-106
64. Allen M., Ishida-Yamamoto A., McGrath J., et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest 81 (2001) 969-976
65. Nair R.P., Stuart P.E., Nistor I., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78 (2006) 827-851
66. Chang Y.T., Chou C.T., Shiao Y.M., et al. Psoriasis vulgaris in Chinese individuals is associated with PSORS1C3 and CDSN genes. Br J Dermatol 155 (2006) 663-669
67. Ameen M., Allen M.H., Fisher S.A., et al. Corneodesmosin (CDSN) gene association with psoriasis vulgaris in Caucasian but not in Japanese populations. Clin Exp Dermatol 30 (2005) 414-418
68. Tomfohrde J., Silverman A., Barnes R., et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264 (1994) 1141-1145
69. Birnbaum R.Y., Zvulunov A., Hallel-Halevy D., et al. Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet 38 (2006) 749-751
70. Capon F., Novelli G., Semprini S., et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 112 (1999) 32-35
71. Hoffjan S., and Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 157 (2007) 441-449
72. Giardina E., Sinibaldi C., Chini L., et al. Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. Hum Hered 61 (2006) 229-236